Grants Funded
Grant applicants for the 2024 cycle requested a total of nearly $3 million dollars. The PSF Study Section Subcommittees of Basic & Translational Research and Clinical Research evaluated more than 100 grant applications on the following topics:
The PSF awarded research grants totaling over $650,000 dollars to support more than 20 plastic surgery research proposals.
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
IGF-1 Nanoparticles to Improve Functional Recovery after Peripheral Nerve Injury
Philip Hanwright MD
2017
Johns Hopkins University-School of Medicine
Research Fellowship
Peripheral Nerve, Hand or Upper Extremity
Peripheral nerve injury (PNI) is a common and challenging problem with many patients experiencing persistent deficits despite optimal intervention. Poor outcomes result primarily from prolonged periods of latency prior to reinnervation. Over time, the absence of target muscle innervation causes irreversible atrophy that limits functional motor recovery. Further hindering outcomes, chronically denervated Schwann cells (SC) within the distal nerve stump senesce and lose their capacity to support regenerating axons.
Augmentation of the growth hormone (GH) axis has emerged as a promising therapeutic approach, the effects of which are primarily mediated by Insulin-like Growth Factor 1 (IGF-1). IGF-1 acts on neurons to speed axonal regeneration, and importantly, also acts independently on denervated muscle and SCs to limit denervation induced atrophy and senescence, respectively.
Despite promising experimental results, these therapies have not reached clinical practice. This is largely due to the multitude of side effects caused by systemic administration, in addition to the need for daily re-dosing injections.
To overcome these obstacles, we developed biodegradable nanoparticles (NPs) to encapsulate and slowly release small amounts of IGF-1 over a prolonged period of time. These can be administered locally to desired tissues in a depot-like fashion to mitigate systemic effects and eliminate the need for frequent re-dosing.
The first aim of this project is to mechanistically evaluate the effects of locally delivered IGF-1 NPs on denervated muscle and nerve, and to determine optimal dosing. IGF-1 NPs will be administered in a depot-like fashion to denervated muscle groups and along the distal nerve stump. Histologic analysis will assess the degree of muscle atrophy and SC senescence.
The second aim of this study will evaluate the effects of IGF-1 NPs on functional recovery after a period of denervation. We will use a forearm chronic denervation model in which the median nerve is transected and left in discontinuity for a period of time, followed by a proximal ulnar nerve to distal median nerve transfer. The experimental group will receive IGF-1 NP therapy, administered at the site of nerve transection, around the exposed distal nerve stump, and injected into the denervated forearm muscle group. The results from this study will provide important information on the efficacy of local, sustained release IGF-1 and its ability to offset the effects of dene
